share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4：持股变动声明-董事 Collins James J.
美股SEC公告 ·  07/12 16:18
Moomoo AI 已提取核心信息
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
詹姆斯·柯林斯与Senti Biosciences, Inc. (SNTI.US)有关，于2024年7月10日与该公司的股票进行了交易。具体交易细节，如交易股数、交易价格和持股比例等，尚未披露。对于投资者了解内部人员行为对其投资决策的影响，这些信息至关重要。
詹姆斯·柯林斯与Senti Biosciences, Inc. (SNTI.US)有关，于2024年7月10日与该公司的股票进行了交易。具体交易细节，如交易股数、交易价格和持股比例等，尚未披露。对于投资者了解内部人员行为对其投资决策的影响，这些信息至关重要。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息